Into the future with novel emerging therapies for haemophilia

1. Lane S. Haemorrhagic diathesis: successful transfusion of blood. Lancet 1940; 41(i): 185-188.10.1016/S0140-6736(00)40031-0Search in Google Scholar

2. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci USA 1982; 79(21): 6461-4.10.1073/pnas.79.21.6461Search in Google Scholar

3. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312(5992): 326-30.10.1038/312326a0Search in Google Scholar

4. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312(5992): 330-7.10.1038/312330a0Search in Google Scholar

5. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984; 312(5992): 337-42.10.1038/312337a0Search in Google Scholar

6. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312(5992): 342-7.10.1038/312342a0Search in Google Scholar

7. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369(24): 2313-23. doi: 10.1056/NEJMoa1305074.Search in Google Scholar

8. Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123(3): 317-25. doi: 10.1182/blood-2013-10-529974.Search in Google Scholar

9. Collins PW, Fischer K, Morfini M, et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.10.1111/j.1365-2516.2010.02370.xSearch in Google Scholar

10. Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015; 13(5): 743-54. doi: 10.1111/jth.12864.Search in Google Scholar

11. Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21(5): 492-7. doi: 10.1038/nm.3847.Search in Google Scholar

12. Müller J, Isermann B, Dücker C, et al. An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. Chem Biol 2009; 16(4): 442-51. doi: 10.1016/j.chembiol.2009.03.007.Search in Google Scholar

13. Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 2014; 124(20): 3165-71. doi: 10.1182/blood-2014-07-585737.Search in Google Scholar